Taxanes in adjuvant breast cancer setting: which standard in Europe?
about
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India.First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysisA genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patientsEconomic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.The taxane limbo: how low can we go?
P2860
Taxanes in adjuvant breast cancer setting: which standard in Europe?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Taxanes in adjuvant breast cancer setting: which standard in Europe?
@ast
Taxanes in adjuvant breast cancer setting: which standard in Europe?
@en
type
label
Taxanes in adjuvant breast cancer setting: which standard in Europe?
@ast
Taxanes in adjuvant breast cancer setting: which standard in Europe?
@en
prefLabel
Taxanes in adjuvant breast cancer setting: which standard in Europe?
@ast
Taxanes in adjuvant breast cancer setting: which standard in Europe?
@en
P2093
P1476
Taxanes in adjuvant breast cancer setting: which standard in Europe?
@en
P2093
Emmanuelle Bourbouloux
Henri Roché
Mario Campone
Pierre Fumoleau
Pierre Kerbrat
P304
P356
10.1016/J.CRITREVONC.2005.04.003
P577
2005-09-01T00:00:00Z